2) Novo Nordisk's CagriSema (cagrilintide and semaglutide), a fixed-dose combination of an amylin analogue and GLP-1 agonist for obesity and type 2 diabetes and successor to the company's big ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback